Follow The Filings

NRIX Nurix Therapeutics Inc.

Health Care, filed as Nurix Therapeutics Inc (COMMON STOCK), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • Max 0.3%
  • $44M
  • 1 add

In 2026 Q2 Cathie Wood added to Nurix Therapeutics.

Who owns this now

Largest portfolio weights among holders, up to 0.3% (Cathie Wood, Ark Investment Management). Not free-float ownership.

  1. Cathie Wood Add 0.28%

Who owns NRIX

Sorted by value, long equity only, as of 2026 Q2.

History
Cathie Wood, Ark Investment Management 0.28%, was 0.21% Add +4.2% 1,793,196 $44M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by NRIX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All NRIX insider trades
  • None no insider bought on the open market
  • $529K sold by 1 insider outside a trading plan
  • $4M sold by 3 insiders under 10b5-1 plans
  1. Gwenn Hansen Chief Scientific Officer
    Planned sale
    $36K 1,452 shares at $25.00 1.2% of stake
    Traded Oct 15 Filed Oct 15
    ↗
  2. Julia P Gregory Director
    Sale
    $529K 22,583 shares at $23.40 68% of stake
    Traded Oct 14 Filed Oct 14
    ↗
  3. Christine Ring Chief Legal Officer
    Planned sale
    $134K 5,786 shares at $23.19 39% of stake
    Traded Oct 2 Filed Oct 2
    ↗
  4. Christine Ring Chief Legal Officer
    Planned sale
    $149K 5,787 shares at $25.76 39% of stake
    Traded Sep 2 Filed Sep 2
    ↗
  5. Gwenn Hansen Chief Scientific Officer
    Planned sale
    $37K 1,452 shares at $25.47 1.2% of stake
    Traded Sep 1 Filed Sep 1
    ↗
  6. Gwenn Hansen Chief Scientific Officer
    Planned sale
    $109K 4,356 shares at $25.00 3.6% of stake
    Traded Aug 5 Filed Aug 5
    ↗
  7. Gwenn Hansen Chief Scientific Officer
    Planned sale
    $100K 4,111 shares at $24.36 3.4% of stake
    Traded Aug 4 Filed Aug 5
    ↗
  8. Hans Van Houte CFO
    Planned sale
    $116K 4,761 shares at $24.36 11% of stake
    Traded Aug 4 Filed Aug 4
    ↗
  9. Christine Ring Chief Legal Officer
    Planned sale
    $382K 16,589 shares at $23.05 65% of stake
    Traded Aug 3 Filed Aug 3
    ↗
  10. Christine Ring Chief Legal Officer
    Planned sale
    $259K 11,008 shares at $23.56 45% of stake
    Traded Jul 2 Filed Jul 2
    ↗
  11. Christine Ring Chief Legal Officer
    Planned sale
    $581K 28,935 shares at $20.06 68% of stake
    Traded Jun 25 Filed Jun 25
    ↗
  12. Gwenn Hansen Chief Scientific Officer
    Planned sale
    $108K 5,394 shares at $20.00 4.5% of stake
    Traded Jun 25 Filed Jun 25
    ↗
  13. Christine Ring Chief Legal Officer
    Planned sale
    $135K 8,148 shares at $16.60 38% of stake
    Traded Jun 2 Filed Jun 2
    ↗
  14. Hans Van Houte CFO
    Planned sale
    $233K 14,055 shares at $16.60 27% of stake
    Traded May 5 Filed May 5
    ↗
  15. Christine Ring Chief Legal Officer
    Planned sale
    $138K 8,148 shares at $16.96 31% of stake
    Traded May 4 Filed May 4
    ↗

Also filed in the last 12 months, not counted as buying or selling: 58 option exercises and 15 sales to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 16 shown.

Filed Form Detail Links
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 1.01,7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.07,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 4 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue — $54.55M $83.98M
Net income -$143.95M -$193.57M -$264.46M
Net margin * — -354.9% -314.9%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $295.5M $619.39M $606.82M
Total non-current assets * $60.1M $49.96M $81.32M
Total assets $355.6M $669.34M $688.14M
Total current liabilities $86.96M $95.85M $86.47M
Total non-current liabilities * $68.15M $46.5M $62.92M
Total equity $200.49M $526.99M $538.75M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$81.36M -$172.58M -$249.46M
Cash from investing $68.3M -$257.71M $147.85M
Cash from financing $3.22M $485.67M $238.64M
Net change in cash -$9.85M $55.37M $137.03M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.